An interventional study of Stair and brisk walking combined and Brisk walking in Metabolic Disease, Cardiovascular Diseases and Hypertension, sponsored by Karolinska Institutet. Recruiting at 5 sites in Sweden. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Metabolic Diseases with a site in Sweden — 5 open to participants now, 6 under way, none of them phase 3. Metabolic Diseases · Sweden.
Among the 21 studies in Metabolic Diseases with a site in Sweden, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 21st registered.
765 studies on the registry are indexed under Metabolic Diseases; 194 are open to participants now.
Browse Metabolic Diseases studies →5 of the 21 studies in Metabolic Diseases with a site in Sweden are open now. Recruiting first, the newest first:
Chalmers University of Technology · Sites in Sweden
Ages 18–70 · Healthy volunteers
Region Skane · Sites in Sweden
Ages 25+
Göteborg University · Sites in Sweden
Ages 6+ · Healthy volunteers
Sahlgrenska University Hospital · Sites in Sweden
Ages 9–14
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 135 Metabolic Diseases studies recruiting now, 47 (35%) set no upper age limit and 64 (47%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 50 across 524 interventional studies indexed under Metabolic Diseases.
Median enrollment 71 across the 17 interventional studies, 120 across the 4 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 21 have an industry lead sponsor. The 10 most frequent:
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Karolinska Institutet has 1 study filed under Metabolic Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Metabolic Diseases with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973408Chalmers University of TechnologyThe SWITCH Dietary and Behavioural Intervention Study | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Metabolic Diseases with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial investigates whether incorporating stair walking into daily routines improves physical health in adults at risk of lifestyle-related conditions such as hypertension, type 2 diabetes, and cardiovascular disease. Participants will be randomized into three groups: (1) stair walking combined with brisk walking, (2) brisk walking alone, and (3) a control group receiving standard lifestyle advice without specific exercise instructions, stratified by age (\<65 y/o, v >=65) and site.
The primary objective is to assess whether the combination of stair and brisk walking leads to greater reductions in systolic blood pressure compared to brisk walking alone or standard care. Secondary outcomes include changes in cardiometabolic risk factors.
Participants in the stair walking group will be instructed to climb ≥250 steps per day (\~5.5 minutes/day or \~37.5 minutes/week), or complete an equivalent elevation via inclined slopes, along with ≥75 minutes of brisk walking per week. Those in the brisk walking group will walk ≥150 minutes per week. The control group will receive general lifestyle advice but no tailored physical activity goals or feedback.
Participants in both active groups will aim to double their baseline activity levels. Physical activity will be continuously monitored using wearable devices. The active groups will receive personalized feedback and motivational support throughout the 6-month intervention period.
If effective, this study may offer a simple, scalable, and low-cost intervention model for use in clinical and public health settings, emphasizing personalized goals, remote monitoring, and behavioral support.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men and women aged 35 years or older with increased cardiometabolic risk, defined by all of the following:
Physically inactive lifestyle, defined as either:
Exclusion Criteria
Medical to physical activity (based on FYSS 2021, p. 182):
Other exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will double their baseline physical activity levels by combining stair walking and brisk walking. The stair walking goal is ≥250 steps per day (equivalent to \~37.5-45 meters elevation or 15 floor levels), totaling \~37.5 minutes per week. In addition, they will complete ≥75 minutes of brisk walking per week.
Behavioral: Stair and brisk walking combined
Participants will double their baseline physical activity levels by engaging in brisk walking only, with a minimum target of \>150 minutes per week.
Behavioral: Brisk walking
Participants will receive general lifestyle advice aligned with current physical activity guidelines but will not be provided with specific exercise instructions, personalized activity targets, or feedback. They will wear the same activity monitor as the intervention groups, but without access to feedback or goal-setting features.
Behavioral: Standard care
See arms.
See arms.
See arms.
Systolic Blood Pressure (SBP) at 6 months
Office systolic blood pressure (SBP) at 6-month follow-up, adjusted for baseline values. SBP is a validated and widely accepted surrogate marker for cardiovascular morbidity and mortality, as well as overall health risk.
Time frame: 6 months
Diastolic Blood Pressure (DBP)
Office diastolic blood pressure (DBP) at 6-month follow-up, adjusted for baseline values. DBP is a clinically relevant indicator of cardiovascular risk and contributes to the assessment of overall blood pressure control.
Time frame: 6 months
HOMA-index
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 6-month follow-up, adjusted for baseline values. HOMA-IR is a validated surrogate marker of insulin resistance and metabolic risk, commonly used in cardiometabolic research.
Time frame: 6 months
HbA1c
Hemoglobin A1c (HbA1c) at 6-month follow-up, adjusted for baseline values. HbA1c reflects average blood glucose levels over the preceding 2-3 months and is a standard marker for assessing glycemic control and diabetes risk.
Time frame: 6 months
LDL cholesterol
Low-Density Lipoprotein (LDL) cholesterol at 6-month follow-up, adjusted for baseline values. LDL cholesterol is a key biomarker for cardiovascular risk and a primary target in lipid-lowering therapies.
Time frame: 6 months
Triglycerides
Triglycerides (TG) at 6-month follow-up, adjusted for baseline levels. Elevated TG are associated with increased cardiovascular risk and are a core component of the metabolic syndrome.
Time frame: 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Blood pressure (systolic and diastolic), BMI, sex, age, HOMA-index, HbA1c, Triglycerides, LDL will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Started Nov 2025 (actual). Primary completion is estimated for Jun 2028, 31 months after the start.
Of 183 non-industry interventional studies with no phase under Metabolic Diseases, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 31 months is above that.
Counting every sponsor, half of 202 studies reached it within 22 months; a quarter within 10 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2028 → Jun 2028 and completion May 2029 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.